DMAA
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Drugs Made In America Acquisition Corp. (DMAA) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Momentum (B-); its weakest is Value (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | F (0.1) | D+ (1.6) | D (1.5) | B- (3.0) | C+ (2.5) | D+ (1.7) |
| 2026-11-04 | F (0.1) | D+ (1.5) | D (1.5) | B- (3.0) | C+ (2.5) | D+ (1.7) |
| 2026-10-28 | F (0.1) | D (1.5) | D (1.5) | B- (2.9) | C+ (2.5) | D+ (1.7) |
| 2026-10-21 | F (0.1) | D (1.5) | D (1.5) | C+ (2.8) | C+ (2.5) | D+ (1.7) |
| 2026-10-14 | F (0.1) | D (1.4) | D (1.5) | C+ (2.7) | C+ (2.5) | D+ (1.6) |